All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Roche is the latest company to have clinical trials with a checkpoint inhibitor put on hold by the U.S. Food and Drug Administration (FDA). Trials with atezolizumab were put on hold on September 18th, and follows the decision by the FDA in July this year to call a stop to clinical trials with Merck’s pembrolizumab, as well as a partial halt on trials with Bristol-Myers Squibb’s nivolumab, AstraZeneca’s durvalumab and MerckKGaA and Pfizer's avelumab. All of these were also being tested in combination therapies for MM.
This domino effect follows a higher than average number of deaths in the pembrolizumab trials, which raised concerns that there may be an inherent safety issue with this class of drug when used in certain combinations – see previous MM Hub article. This has bought the FDA more time to gather details, as patient safety remains their priority.
In this latest decision, the trials called to a halt were early phase Ib and phase Ib/II trials, assessing the efficacy of atezolizumab in combination with either lenalidomide or pomalidomide to treat Relapsed/Refractory Multiple Myeloma (RRMM).
Atezolizumab is a monoclonal antibody against PD-L1 (programmed death-ligand 1), which already has FDA approval to treat a number of other cancers, including lung and bladder cancer. Interestingly, no safety concerns have been raised prior to this, suggesting that only in this setting may it pose a problem. Whilst the role of the PD-1/PD-L1 axis is well understood, the interplay with other signals specifically in MM has yet to be fully described, as well as the synergistic effect of combining the different regimens, in particular with other immunomodulatory drugs (IMiDs). Answering this key question is likely to be on the agenda in many research labs going forward.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox